Enveda reports early clinical findings for ENV-308
Enveda →Enveda reported Phase 1 findings for ENV-308, an investigational oral candidate being developed for metabolic health and maintenance after weight loss. The company described favorable tolerability and exploratory biomarker findings in healthy volunteers. It said the study evaluated safety, tolerability and the drug’s behavior in the body, rather than weight-loss efficacy or other metabolic outcomes. Enveda planned further clinical studies to test potential benefits after discontinuation of GLP-1 treatment. Findings from animal studies were presented separately from human results. ENV-308 remained unapproved, and the company cautioned that earlier research might not predict results in subsequent clinical development or regulatory review.